India, Aug. 27 -- Eli Lilly and Company (LLY) Wednesday announced positive topline results from the primary overall survival analysis of the Phase 3 monarchE study of Verzenio in early breast cancer.
Data showed that treatment with two years of Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone in patients with hormone receptor positive (HR+), HER2-, node-positive, high-risk early breast cancer.
In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit.
googletag.cmd.push(function() { googletag.display('div-gpt...